• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一项针对既往接受过治疗的晚期胃癌患者，比较每周或每3周剂量的纳米白蛋白结合型紫杉醇与每周剂量的聚氧乙烯蓖麻油基紫杉醇的随机III期试验（ABSOLUTE试验）。

A randomized Phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial).

作者信息

Koizumi Wasaburo, Morita Satoshi, Sakata Yuh

机构信息

Department of Gastroenterology, Kitasato University School of Medicine, Sagamihara-shi, Kanagawa

Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto-shi, Kyoto.

出版信息

Jpn J Clin Oncol. 2015 Mar;45(3):303-6. doi: 10.1093/jjco/hyu205. Epub 2014 Dec 16.

DOI:10.1093/jjco/hyu205
PMID:25516635
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4340275/
Abstract

Paclitaxel is an agent widely used in second-line chemotherapy for advanced gastric cancer. The aim of this trial is to evaluate the efficacy and safety of 3-weekly or weekly doses of nanoparticle albumin-bound-paclitaxel compared with weekly doses of Cremophor-based paclitaxel in patients with unresectable or recurrent gastric cancer refractory to first-line chemotherapy comprising fluoropyrimidines. A total of 730 patients will be enrolled from 72 institutions. The primary endpoint is the overall survival, and the secondary endpoints are progression-free survival, time to treatment failure, overall response rate, disease control rate, quality of life (by using the EQ-5D system) and safety.

摘要

紫杉醇是一种广泛用于晚期胃癌二线化疗的药物。本试验的目的是评估每3周或每周一次剂量的纳米白蛋白结合型紫杉醇与每周一次剂量的聚氧乙烯蓖麻油基紫杉醇相比，在一线含氟嘧啶化疗难治的不可切除或复发性胃癌患者中的疗效和安全性。将从72个机构招募总共730名患者。主要终点是总生存期，次要终点是无进展生存期、治疗失败时间、总缓解率、疾病控制率、生活质量（使用EQ-5D系统）和安全性。

相似文献

1
A randomized Phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial).一项针对既往接受过治疗的晚期胃癌患者，比较每周或每3周剂量的纳米白蛋白结合型紫杉醇与每周剂量的聚氧乙烯蓖麻油基紫杉醇的随机III期试验（ABSOLUTE试验）。
Jpn J Clin Oncol. 2015 Mar;45(3):303-6. doi: 10.1093/jjco/hyu205. Epub 2014 Dec 16.
2
Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.每周紫杉醇联合雷莫芦单抗对比每周nab-紫杉醇联合雷莫芦单抗治疗一线治疗失败的不可切除的晚期或复发性伴腹膜转移的胃癌：由日本西部肿瘤协作组（West Japan Oncology Group）开展的 P-SELECT 试验（WJOG10617G）-一项随机 II 期试验
BMC Cancer. 2020 Jun 12;20(1):548. doi: 10.1186/s12885-020-07047-1.
3
Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.奈达铂紫杉醇对比既往治疗的晚期胃癌患者中的溶剂型紫杉醇（ABSOLUTE）：一项开放标签、随机、非劣效、3 期临床试验。
Lancet Gastroenterol Hepatol. 2017 Apr;2(4):277-287. doi: 10.1016/S2468-1253(16)30219-9. Epub 2017 Jan 19.
4
A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.一项纳武利尤单抗联合紫杉醇白蛋白在先前治疗的晚期胃癌患者中的 II 期研究。
Eur J Cancer. 2018 Mar;91:86-91. doi: 10.1016/j.ejca.2017.11.032. Epub 2018 Jan 30.
5
A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302).一项剂量减少的 nab-紫杉醇治疗既往治疗的晚期或复发性胃癌患者的 II 期临床试验（OGSG 1302）。
Int J Clin Oncol. 2020 Dec;25(12):2035-2043. doi: 10.1007/s10147-020-01768-w. Epub 2020 Sep 14.
6
A Phase II Study of Tri-weekly Low-dose Nab-paclitaxel Chemotherapy for Patients with Advanced Gastric Cancer.晚期胃癌患者每三周一次低剂量纳米白蛋白结合型紫杉醇化疗的II期研究
Anticancer Res. 2018 Dec;38(12):6911-6917. doi: 10.21873/anticanres.13068.
7
Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.II/III期每周一次白蛋白结合型紫杉醇联合吉西他滨或卡铂对比吉西他滨/卡铂作为转移性三阴性乳腺癌患者一线治疗的研究（tnAcity研究）：一项随机对照试验的研究方案
Trials. 2015 Dec 16;16:575. doi: 10.1186/s13063-015-1101-7.
8
Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer.白蛋白结合型紫杉醇纳米粒二线治疗不可切除或复发性胃癌的 II 期临床试验。
Cancer Sci. 2014 Jul;105(7):812-7. doi: 10.1111/cas.12419. Epub 2014 Jul 7.
9
ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).ABOUND.2L+：一项纳米白蛋白结合紫杉醇联合或不联合 CC-486 二线治疗晚期非鳞状非小细胞肺癌（NSCLC）的随机 2 期研究。
Cancer. 2018 Dec 15;124(24):4667-4675. doi: 10.1002/cncr.31779. Epub 2018 Nov 1.
10
Phase II multi-institutional prospective trial of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer refractory to fluoropyrimidine with modified dose reduction criteria (CCOG1303).多中心 II 期前瞻性试验：纳武利尤单抗联合伊匹木单抗治疗既往接受过治疗的晚期胃或胃食管结合部腺癌患者的随机、双盲、安慰剂对照、III 期临床研究（CheckMate 649）
Int J Clin Oncol. 2020 Oct;25(10):1793-1799. doi: 10.1007/s10147-020-01724-8. Epub 2020 Jun 21.

引用本文的文献

1
PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study.PD-1 抑制剂联合白蛋白紫杉醇和安罗替尼二线治疗转移性胃癌患者的单中心、单臂、Ⅱ期研究。
Invest New Drugs. 2024 Apr;42(2):171-178. doi: 10.1007/s10637-024-01425-3. Epub 2024 Feb 12.
2
Study on the thermal stability of nab-paclitaxel during hyperthermic intraperitoneal chemotherapy.纳武利尤单抗联合紫杉醇治疗恶性胸腔积液的疗效及安全性
BMC Pharmacol Toxicol. 2023 Mar 1;24(1):13. doi: 10.1186/s40360-023-00653-2.
3
Combination carboplatin and nab-paclitaxel as a first-line treatment for advanced thymic carcinoma.卡铂与纳米白蛋白结合型紫杉醇联合作为晚期胸腺癌的一线治疗方案。
Invest New Drugs. 2023 Feb;41(1):115-121. doi: 10.1007/s10637-023-01327-w. Epub 2023 Jan 12.
4
Carboplatin plus nanoparticle albumin-bound paclitaxel for the treatment of thymic carcinoma.卡铂联合纳米白蛋白结合型紫杉醇治疗胸腺癌。
Mol Clin Oncol. 2022 Apr;16(4):87. doi: 10.3892/mco.2022.2520. Epub 2022 Feb 21.
5
Long-term response on letrozole for gastric cancer: A case report.来曲唑治疗胃癌的长期疗效：一例报告。
Medicine (Baltimore). 2021 May 28;100(21):e26146. doi: 10.1097/MD.0000000000026146.
6
Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer.奈达铂联合顺铂与多西他赛联合顺铂一线治疗非小细胞肺癌的比较
Sci Rep. 2017 Sep 7;7(1):10760. doi: 10.1038/s41598-017-11404-9.
7
Successful Long-term Management with a Single Administration of Tri-weekly Nab-paclitaxel in a Patient with Advanced Gastric Cancer with Peritoneal Dissemination.晚期胃癌伴腹膜播散患者每三周单次给予纳米白蛋白结合型紫杉醇的长期成功管理。
Intern Med. 2017;56(8):921-923. doi: 10.2169/internalmedicine.56.7783. Epub 2017 Apr 15.
8
A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer.一项关于S-1联合纳米白蛋白结合型紫杉醇治疗不可切除或复发性胃癌患者的I期研究。
Gastric Cancer. 2017 Mar;20(2):350-357. doi: 10.1007/s10120-016-0614-4. Epub 2016 May 17.
9
Paralytic ileus due to a novel anticancer drug, nab-paclitaxel: A case report.新型抗癌药物纳米白蛋白结合型紫杉醇所致麻痹性肠梗阻：一例报告
Mol Clin Oncol. 2016 May;4(5):824-826. doi: 10.3892/mco.2016.782. Epub 2016 Feb 16.
10
Response to chemotherapy with carboplatin plus albumin-bound paclitaxel in a patient with lymphoepithelioma-like thymic carcinoma: A case report.卡铂联合白蛋白结合型紫杉醇治疗淋巴上皮瘤样胸腺癌1例：病例报告
Mol Clin Oncol. 2016 May;4(5):715-718. doi: 10.3892/mco.2016.803. Epub 2016 Mar 7.

本文引用的文献

1
Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407).一项随机II期研究，比较最佳可用的含5-氟尿嘧啶方案二线化疗与每周给予紫杉醇用于对含5-氟尿嘧啶方案难治的伴有严重腹膜转移的晚期胃癌（JCOG0407）。
Gastric Cancer. 2016 Jul;19(3):902-10. doi: 10.1007/s10120-015-0542-8. Epub 2015 Sep 19.
2
Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer.白蛋白结合型紫杉醇纳米粒二线治疗不可切除或复发性胃癌的 II 期临床试验。
Cancer Sci. 2014 Jul;105(7):812-7. doi: 10.1111/cas.12419. Epub 2014 Jul 7.
3
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.多西他赛对比积极症状控制治疗难治性胃食管腺癌（COUGAR-02）：一项开放标签、3 期随机对照试验。
Lancet Oncol. 2014 Jan;15(1):78-86. doi: 10.1016/S1470-2045(13)70549-7. Epub 2013 Dec 10.
4
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.随机、开放标签、III 期研究比较了伊立替康与紫杉醇在氟嘧啶加铂类化疗失败后无严重腹膜转移的晚期胃癌患者中的疗效：WJOG4007 试验。
J Clin Oncol. 2013 Dec 10;31(35):4438-44. doi: 10.1200/JCO.2012.48.5805. Epub 2013 Nov 4.
5
Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.预处理后胃癌的挽救化疗：比较化疗联合最佳支持治疗与单纯最佳支持治疗的随机 III 期试验。
J Clin Oncol. 2012 May 1;30(13):1513-8. doi: 10.1200/JCO.2011.39.4585. Epub 2012 Mar 12.
6
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).伊立替康对比最佳支持治疗作为胃癌二线化疗的生存优势——德国肿瘤内科学会（AIO）的一项随机 III 期研究。
Eur J Cancer. 2011 Oct;47(15):2306-14. doi: 10.1016/j.ejca.2011.06.002.
7
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.氟尿嘧啶对比伊立替康联合顺铂与S-1治疗转移性胃癌：一项随机3期研究。
Lancet Oncol. 2009 Nov;10(11):1063-9. doi: 10.1016/S1470-2045(09)70259-1. Epub 2009 Oct 7.
8
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.S-1联合顺铂与单用S-1作为晚期胃癌一线治疗的疗效比较（SPIRITS试验）：一项III期试验
Lancet Oncol. 2008 Mar;9(3):215-21. doi: 10.1016/S1470-2045(08)70035-4. Epub 2008 Feb 20.
9
Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer.每周一次紫杉醇用于晚期或复发性胃癌的二线化疗。
Gastric Cancer. 2006;9(1):14-8. doi: 10.1007/s10120-005-0351-6.
10
Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies.ABI-007（一种新型紫杉醇纳米颗粒制剂）用于晚期非血液系统恶性肿瘤患者的I期及药代动力学试验。
J Clin Oncol. 2005 Nov 1;23(31):7785-93. doi: 10.1200/JCO.2004.00.6148.